In silico approach: biological prediction of nordentatin derivatives as anticancer agent inhibitors in the cAMP pathway

• Published in: RSC advances 2020-11, Vol.10 (70), p.42733-42743
• Main Authors: Abdjan, Muhammad Ikhlas, Aminah, Nanik Siti, Siswanto, Imam, Thant, Tin Myo, Kristanti, Alfinda Novi, Takaya, Yoshiaki
• Format: Article
• Language: English
• Subjects: Anticancer properties; Binding; Cell division; Chemistry; Density functional theory; Derivatives; Drugs; Free energy; Gene expression; Ligands; Molecular docking; Molecular dynamics; Proteins; Residues
• ISSN: 2046-2069; 2046-2069
• DOI: 10.1039/d0ra07838g

A combination of computational techniques has been carried out to predict the binding of nordentatin derivatives based on pyranocoumarin semi-synthesis with the target protein from the expression of the PDE4B gene. The inhibition of the cAMP pathway is the main target of anti-cancer drugs, which is responsible for uncontrolled cell division in cancer. Modeling was done using a combination of semi-empirical methods and the density functional theory (PM3-DFT/6-31G*/B3LYP) to obtain the optimal structure of a small ligand that could be modeled. Studies on the interaction of the ligands and amino acid residues on protein targets were carried out using a combination of molecular docking and molecular dynamic simulation. Molecular docking based on functional grid scores showed a very good native ligand pose with an RMSD of 0.93 Å in determining the initial coordinates of the ligand-receptor interactions. Furthermore, the amino acid residues responsible for interaction through H-bonds were Tyr103, His104, His177, Met217, and Gln313. The binding free energy (kcal mol ) results of the candidates were PS-1 (-36.84 ± 0.31), PS-2 (-35.34 ± 0.28), PS-3 (-26.65 ± 0.30), PS-5 (-42.66 ± 0.26), PS-7 (-35.33 ± 0.23), and PS-9 (-32.57 ± 0.20), which are smaller than that of the native ligand Z72 (-24.20 ± 0.19), and thus these have good potential as drugs that can inhibit the cAMP pathway. These results provide theoretical information for the efficient inhibition of the cAMP pathway in the future.